SLC5A2 and chronic kidney disease: Under SGLT2 inhibitor price reductions, selected CKD screening strategies were cost-effective even if SGLT2 inhibitor effectiveness against disease progression and all-cause mortality were lower as reported in other clinical trials (eTable 11 in Supplement 1).4 Finally, reducing base-case values for treatment initiation and adherence by 25% to reflect implementation barriers resulted in ICERs for screening every 5 years starting at ages 35 years or 55 years to be $228 400 per QALY gained or $150 800 per QALY gained, respectively (eTable 12 in Supplement 1).